James Quigley
Stock Analyst at Morgan Stanley
(0)
# 4993
Out of 5,243 analysts
27
Total ratings
50.00%
Success rate
-36.14%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Kymera Therapeutics | Maintains: Equal-Weight | 45 49 | 43.54 | 12.54% | 5 | Nov 6, 2024 | |
Novartis | Downgrades: Neutral | 119 121 | 99.05 | 22.16% | 1 | Sep 5, 2024 | |
MorphoSys | Downgrades: Equal-Weight | n/a | n/a | n/a | 6 | Jan 19, 2024 | |
Grifols | Maintains: Neutral | 10 11 | 7.45 | 40.94% | 1 | Dec 5, 2023 | |
Galapagos | Maintains: Equal-Weight | 42 40 | 23.75 | 68.42% | 10 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 12 16 | 4.12 | 288.35% | 3 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 25 | n/a | n/a | 1 | Nov 20, 2017 |